

Antonia Vlahou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8753018/publications.pdf>

Version: 2024-02-01

168
papers

7,021
citations

66343

42
h-index

74163

75
g-index

185
all docs

185
docs citations

185
times ranked

8388
citing authors

#	ARTICLE	IF	CITATIONS
1	RGS14414-Mediated Activation of the 14-3-3 σ in Rodent Perirhinal Cortex Induces Dendritic Arborization, an Increase in Spine Number, Long-Lasting Memory Enhancement, and the Prevention of Memory Deficits. <i>Cerebral Cortex</i> , 2022, 32, 1894-1910.	2.9	5
2	Urine peptidome in combination with transcriptomics analysis highlights MMP7, MMP14 and PCSK5 for further investigation in chronic kidney disease. <i>PLoS ONE</i> , 2022, 17, e0262667.	2.5	12
3	Proteomic Analysis of Mouse Kidney Tissue Associates Peroxisomal Dysfunction with Early Diabetic Kidney Disease. <i>Biomedicines</i> , 2022, 10, 216.	3.2	4
4	Redox Analysis of Atherosclerotic : Application of the α -Method. <i>Methods in Molecular Biology</i> , 2022, 2419, 629-644.	0.9	0
5	Microbiome in Chronic Kidney Disease (CKD): An Omics Perspective. <i>Toxins</i> , 2022, 14, 176.	3.4	22
6	In Situ Peroxidase Labeling Followed by Mass-Spectrometry Reveals TIA1 Interactome. <i>Biology</i> , 2022, 11, 287.	2.8	1
7	Collagen-Derived Peptides in CKD: A Link to Fibrosis. <i>Toxins</i> , 2022, 14, 10.	3.4	15
8	MO379: Collagen-Derived Peptides in CKD: A Link to Fibrosis. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0
9	APEX2-Mediated Proximity Labeling Resolves the DDIT4-Interacting Proteome. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5189.	4.1	1
10	Cardioprotection by selective SGLT-2 inhibitors in a non-diabetic mouse model of myocardial ischemia/reperfusion injury: a class or a drug effect?. <i>Basic Research in Cardiology</i> , 2022, 117, 27.	5.9	21
11	Gene Expression Monotonicity across Bladder Cancer Stages Informs on the Molecular Pathogenesis and Identifies a Prognostic Eight-Gene Signature. <i>Cancers</i> , 2022, 14, 2542.	3.7	3
12	Validation of diagnostic nomograms based on CE-MS urinary biomarkers to detect clinically significant prostate cancer. <i>World Journal of Urology</i> , 2022, 40, 2195-2203.	2.2	4
13	Chronic Empagliflozin Treatment Reduces Myocardial Infarct Size in Nondiabetic Mice Through STAT-3-Mediated Protection on Microvascular Endothelial Cells and Reduction of Oxidative Stress. <i>Antioxidants and Redox Signaling</i> , 2021, 34, 551-571.	5.4	44
14	The urinary proteomics classifier chronic kidney disease 273 predicts cardiovascular outcome in patients with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 811-818.	0.7	26
15	Data Sharing Under the General Data Protection Regulation. <i>Hypertension</i> , 2021, 77, 1029-1035.	2.7	47
16	Mining the Biomarker Potential of the Urine Peptidome: From Amino Acids Properties to Proteases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5940.	4.1	10
17	Developing Novel Drug Candidates and Repurposed Drugs for Prostate Cancer Based on Molecular Profiles. <i>Current Medicinal Chemistry</i> , 2021, 28, 8392-8415.	2.4	2
18	Urinary peptides in heart failure: a link to molecular pathophysiology. <i>European Journal of Heart Failure</i> , 2021, 23, 1875-1887.	7.1	37

#	ARTICLE	IF	CITATIONS
19	Urine peptidome analysis in cardiorenal syndrome reflects molecular processes. <i>Scientific Reports</i> , 2021, 11, 16219.	3.3	7
20	Serum and urinary biomarkers of collagen type I turnover predict prognosis in patients with heart failure. <i>Clinical and Translational Medicine</i> , 2021, 11, e267.	4.0	10
21	Urinary peptidomic profiles to address age-related disabilities: a prospective population study. <i>The Lancet Healthy Longevity</i> , 2021, 2, e690-e703.	4.6	17
22	Molecular Mapping of Urinary Complement Peptides in Kidney Diseases. <i>Proteomes</i> , 2021, 9, 49.	3.5	5
23	Abstract 13262: Improved Rabbit Model of Calcific Aortic Valve Disease Induces Severe Medial Calcification and Stenosis Equivalent to Human Disease. <i>Circulation</i> , 2021, 144, .	1.6	0
24	Proteome-based classification of Nonmuscle Invasive Bladder Cancer. <i>International Journal of Cancer</i> , 2020, 146, 281-294.	5.1	35
25	Proteomics Analysis of Formalin Fixed Paraffin Embedded Tissues in the Investigation of Prostate Cancer. <i>Journal of Proteome Research</i> , 2020, 19, 2631-2642.	3.7	21
26	Drug repurposing in oncology. <i>Lancet Oncology</i> , The, 2020, 21, e543.	10.7	20
27	A Novel Pipeline for Drug Repurposing for Bladder Cancer Based on Patients's Omics Signatures. <i>Cancers</i> , 2020, 12, 3519.	3.7	12
28	Connectivity mapping of glomerular proteins identifies dimethylaminoparthenolide as a new inhibitor of diabetic kidney disease. <i>Scientific Reports</i> , 2020, 10, 14898.	3.3	14
29	Molecular Changes in Tissue Proteome during Prostate Cancer Development: Proof-of-Principle Investigation. <i>Diagnostics</i> , 2020, 10, 655.	2.6	12
30	Insights into Biomechanical and Proteomic Characteristics of Small Diameter Vascular Grafts Utilizing the Human Umbilical Artery. <i>Biomedicines</i> , 2020, 8, 280.	3.2	13
31	Multiplexed MRM-based protein quantification of putative prognostic biomarkers for chronic kidney disease progression in plasma. <i>Scientific Reports</i> , 2020, 10, 4815.	3.3	17
32	Urinary-Based Markers for Bladder Cancer Detection. <i>Société Internationale D'urologie Journal</i> , 2020, 1, 49-61.	0.4	3
33	Proteomics biomarkers for solid tumors: Current status and future prospects. <i>Mass Spectrometry Reviews</i> , 2019, 38, 49-78.	5.4	53
34	Short Term Results of Fibrin Gel Obtained from Cord Blood Units: A Preliminary in Vitro Study. <i>Bioengineering</i> , 2019, 6, 66.	3.5	12
35	Functional secretome analysis reveals Annexin-A1 as important paracrine factor derived from fetal mesenchymal stem cells in hepatic regeneration. <i>EBioMedicine</i> , 2019, 45, 542-552.	6.1	27
36	Urinary peptide panel for prognostic assessment of bladder cancer relapse. <i>Scientific Reports</i> , 2019, 9, 7635.	3.3	12

#	ARTICLE	IF	CITATIONS
37	Applications of multiple reaction monitoring targeted proteomics assays in human plasma. Expert Review of Molecular Diagnostics, 2019, 19, 499-515.	3.1	15
38	Development and Validation of Multiple Reaction Monitoring (MRM) Assays for Clinical Applications. Methods in Molecular Biology, 2019, 1959, 205-223.	0.9	15
39	Protein biomarkers for cardiorenal syndrome. Expert Review of Proteomics, 2019, 16, 325-336.	3.0	6
40	Proteomics based identification of KDM5 histone demethylases associated with cardiovascular disease. EBioMedicine, 2019, 41, 91-104.	6.1	23
41	Impairment of chaperone-mediated autophagy affects neuronal homeostasis through altered expression of DJ-1 and CRMP-2 proteins. Molecular and Cellular Neurosciences, 2019, 95, 1-12.	2.2	11
42	Diagnostic and Prognostic Performance of Secreted Protein Acidic and Rich in Cysteine (SPARC) Assay for Detecting Primary and Recurrent Urinary Bladder Cancer. Proteomics - Clinical Applications, 2019, 13, 1800148.	1.6	7
43	Urinary Glycopeptide Analysis for the Investigation of Novel Biomarkers. Proteomics - Clinical Applications, 2019, 13, e1800111.	1.6	17
44	Implementation of Clinical Proteomics: A Step Closer to Personalized Medicine?. Proteomics - Clinical Applications, 2019, 13, e1800088.	1.6	7
45	Systems biology identifies cytosolic PLA2 as a target in vascular calcification treatment. JCI Insight, 2019, 4, .	5.0	25
46	Cost-effectiveness of screening type 2 diabetes patients for chronic kidney disease progression with the CKD273 urinary peptide classifier as compared to urinary albumin excretion. Nephrology Dialysis Transplantation, 2018, 33, 441-449.	0.7	35
47	Comparison of Urine and Plasma Peptidome Indicates Selectivity in Renal Peptide Handling. Proteomics - Clinical Applications, 2018, 12, e1700163.	1.6	38
48	Plasma proteomic analysis reveals altered protein abundances in cardiovascular disease. Journal of Translational Medicine, 2018, 16, 104.	4.4	48
49	Urinary CE-MS peptide marker pattern for detection of solid tumors. Scientific Reports, 2018, 8, 5227.	3.3	28
50	Clinical Proteomics for Precision Medicine: The Bladder Cancer Case. Proteomics - Clinical Applications, 2018, 12, 1700074.	1.6	21
51	Tissue proteomics studies in the investigation of prostate cancer. Expert Review of Proteomics, 2018, 15, 593-611.	3.0	8
52	The family of 14â€³â€³ proteins and specifically 14â€³â€³ are upâ€³regulated during the development of renal pathologies. Journal of Cellular and Molecular Medicine, 2018, 22, 4139-4149.	3.6	10
53	Evaluation of Peripheral Blood and Cord Blood Platelet Lysates in Isolation and Expansion of Multipotent Mesenchymal Stromal Cells. Bioengineering, 2018, 5, 19.	3.5	11
54	A urinary proteome-based classifier for the early detection of decline in glomerular filtration. Nephrology Dialysis Transplantation, 2017, 32, gfw239.	0.7	73

#	ARTICLE	IF	CITATIONS
55	Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw337.	0.7	62
56	Proteomics in cardiovascular disease: recent progress and clinical implication and implementation. <i>Expert Review of Proteomics</i> , 2017, 14, 117-136.	3.0	34
57	GeLC-MS: A Sample Preparation Method for Proteomics Analysis of Minimal Amount of Tissue. <i>Methods in Molecular Biology</i> , 2017, 1788, 165-175.	0.9	18
58	Identification of novel molecular signatures of IgA nephropathy through an integrative -omics analysis. <i>Scientific Reports</i> , 2017, 7, 9091.	3.3	16
59	Deciphering the disease-related molecular networks using urine proteomics. <i>TrAC - Trends in Analytical Chemistry</i> , 2017, 94, 200-209.	11.4	2
60	Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker. <i>Kidney International Reports</i> , 2017, 2, 1066-1075.	0.8	77
61	NADPH oxidases as drug targets and biomarkers in neurodegenerative diseases: What is the evidence?. <i>Free Radical Biology and Medicine</i> , 2017, 112, 387-396.	2.9	88
62	Association of kidney fibrosis with urinary peptides: a path towards non-invasive liquid biopsies?. <i>Scientific Reports</i> , 2017, 7, 16915.	3.3	67
63	Urinary peptidomics analysis reveals proteases involved in diabetic nephropathy. <i>Scientific Reports</i> , 2017, 7, 15160.	3.3	28
64	Cervical Cancer Cell Line Secretome Highlights the Roles of Transforming Growth Factor-Beta-Induced Protein ig-h3, Peroxiredoxin-2, and NRF2 on Cervical Carcinogenesis. <i>BioMed Research International</i> , 2017, 2017, 1-15.	1.9	39
65	The use of urinary proteomics in the assessment of suitability of mouse models for ageing. <i>PLoS ONE</i> , 2017, 12, e0166875.	2.5	17
66	Ten Years of Proteomics in Bladder Cancer: Progress and Future Directions. <i>Bladder Cancer</i> , 2017, 3, 1-18.	0.4	24
67	Proteomics analysis of bladder cancer invasion: Targeting EIF3D for therapeutic intervention. <i>Oncotarget</i> , 2017, 8, 69435-69455.	1.8	27
68	Urinary Proteomics in Predicting Heart Transplantation Outcomes (uPROPHET)â€”Rationale and database description. <i>PLoS ONE</i> , 2017, 12, e0184443.	2.5	9
69	Proteomics approaches in cervical cancer: focus on the discovery of biomarkers for diagnosis and drug treatment monitoring. <i>Expert Review of Proteomics</i> , 2016, 13, 731-745.	3.0	27
70	Analysis of urinary cathepsin C for diagnosing Papillonâ€”LefÃ©vre syndrome. <i>FEBS Journal</i> , 2016, 283, 498-509.	4.7	14
71	Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study. <i>Clinical Cancer Research</i> , 2016, 22, 4077-4086.	7.0	90
72	High-Throughput LCâ€”MS/MS Proteomic Analysis of a Mouse Model of Mesiotemporal Lobe Epilepsy Predicts Microglial Activation Underlying Disease Development. <i>Journal of Proteome Research</i> , 2016, 15, 1546-1562.	3.7	33

#	ARTICLE	IF	CITATIONS
73	Taking the next step“Advancing bladder cancer management. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 435-436.	1.6	1
74	Desmin and Î±B-crystallin interplay in maintenance of mitochondrial homeostasis and cardiomyocyte survival. Journal of Cell Science, 2016, 129, 3705-3720.	2.0	59
75	Integrative analysis of extracellular and intracellular bladder cancer cell line proteome with transcriptome: improving coverage and validity of “omics findings. Scientific Reports, 2016, 6, 25619.	3.3	12
76	Microhematuria assessment an IBCN consensus“Based upon a critical review of current guidelines. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 437-451.	1.6	25
77	Effect of Heme Oxygenase-1 Deficiency on Glomerular Proteomics. American Journal of Nephrology, 2016, 43, 441-450.	3.1	5
78	BcCluster: A Bladder Cancer Database at the Molecular Level. Bladder Cancer, 2016, 2, 65-76.	0.4	4
79	PeptiCKDb“peptide- and protein-centric database for the investigation of genesis and progression of chronic kidney disease. Database: the Journal of Biological Databases and Curation, 2016, 2016, baw128.	3.0	7
80	Analytical Performance of ELISA Assays in Urine: One More Bottleneck towards Biomarker Validation and Clinical Implementation. PLoS ONE, 2016, 11, e0149471.	2.5	27
81	Silencing of Profilin-1 suppresses cell adhesion and tumor growth via predicted alterations in integrin and Ca ²⁺ signaling in T24M-based bladder cancer models. Oncotarget, 2016, 7, 70750-70768.	1.8	19
82	Comparison of higher energy collisional dissociation and collision“induced dissociation MS/MS sequencing methods for identification of naturally occurring peptides in human urine. Proteomics - Clinical Applications, 2015, 9, 531-542.	1.6	19
83	Protein Interactome of Muscle Invasive Bladder Cancer. PLoS ONE, 2015, 10, e0116404.	2.5	12
84	Comparative Analysis of Label-Free and 8-Plex iTRAQ Approach for Quantitative Tissue Proteomic Analysis. PLoS ONE, 2015, 10, e0137048.	2.5	92
85	FP268MOLECULAR SIMILARITY OF RENAL AGEING AND CKD REVEALED BY URINARY PROTEOMICS. Nephrology Dialysis Transplantation, 2015, 30, iii156-iii157.	0.7	0
86	Developing proteomic biomarkers for bladder cancer: towards clinical application. Nature Reviews Urology, 2015, 12, 317-330.	3.8	69
87	Capillary zone electrophoresis on“line coupled to mass spectrometry: A perspective application for clinical proteomics. Proteomics - Clinical Applications, 2015, 9, 453-468.	1.6	43
88	Proteomic biomarkers in kidney disease: issues in development and implementation. Nature Reviews Nephrology, 2015, 11, 221-232.	9.6	101
89	CE“MS“based proteomics in biomarker discovery and clinical application. Proteomics - Clinical Applications, 2015, 9, 322-334.	1.6	68
90	Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides. Journal of the American Society of Nephrology: JASN, 2015, 26, 1999-2010.	6.1	205

#	ARTICLE	IF	CITATIONS
91	New insights in molecular mechanisms involved in chronic kidney disease using high-resolution plasma proteome analysis. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1842-1852.	0.7	64
92	Epidemiologic Design and Analysis for Proteomic Studies: A Primer on -Omic Technologies. <i>American Journal of Epidemiology</i> , 2015, 181, 635-647.	3.4	30
93	SRM/MRM targeted proteomics as a tool for biomarker validation and absolute quantification in human urine. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 1441-1454.	3.1	46
94	Biological Sample Collection for Clinical Proteomics: Existing SOPs. <i>Methods in Molecular Biology</i> , 2015, 1243, 3-27.	0.9	22
95	Targeting the Proteome of Cellular Fractions: Focus on Secreted Proteins. <i>Methods in Molecular Biology</i> , 2015, 1243, 29-41.	0.9	1
96	Comparison of Depletion Strategies for the Enrichment of Low-Abundance Proteins in Urine. <i>PLoS ONE</i> , 2015, 10, e0133773.	2.5	39
97	Identification of ageing-associated naturally occurring peptides in human urine. <i>Oncotarget</i> , 2015, 6, 34106-34117.	1.8	31
98	Clinical proteomics in obstetrics and neonatology. <i>Expert Review of Proteomics</i> , 2014, 11, 75-89.	3.0	31
99	New Selective Peptidyl Di(chlorophenyl) Phosphonate Esters for Visualizing and Blocking Neutrophil Proteinase 3 in Human Diseases. <i>Journal of Biological Chemistry</i> , 2014, 289, 31777-31791.	3.4	38
100	Advances in urinary proteome analysis and applications in systems biology. <i>Bioanalysis</i> , 2014, 6, 2549-2569.	1.5	17
101	Discovery and validation of urinary biomarkers for detection of renal cell carcinoma. <i>Journal of Proteomics</i> , 2014, 98, 44-58.	2.4	64
102	Proteome-Based Systems Biology Analysis of the Diabetic Mouse Aorta Reveals Major Changes in Fatty Acid Biosynthesis as Potential Hallmark in Diabetes Mellitus-Associated Vascular Disease. <i>Circulation: Cardiovascular Genetics</i> , 2014, 7, 161-170.	5.1	22
103	Putting value in biomarker research and reporting. <i>Journal of Proteomics</i> , 2014, 96, A1-A3.	2.4	19
104	Considerations on the use of urine markers in the management of patients with high-grade non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1069-1077.	1.6	34
105	Urinary proteomics and molecular determinants of chronic kidney disease: possible link to proteases. <i>Expert Review of Proteomics</i> , 2014, 11, 535-548.	3.0	24
106	Considerations on the use of urine markers in the management of patients with low-/intermediate-risk non-muscle invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1061-1068.	1.6	39
107	IMAC Fractionation in Combination with LC-MS Reveals H2B and NIF-1 Peptides As Potential Bladder Cancer Biomarkers. <i>Journal of Proteome Research</i> , 2013, 12, 3969-3979.	3.7	20
108	Network views for personalized medicine. <i>Proteomics - Clinical Applications</i> , 2013, 7, 384-387.	1.6	13

#	ARTICLE	IF	CITATIONS
109	Clinical applications of capillary electrophoresis coupled to mass spectrometry in biomarker discovery: Focus on bladder cancer. <i>Proteomics - Clinical Applications</i> , 2013, 7, 779-793.	1.6	26
110	Characterization and comparative performance of lentiviral vector preparations concentrated by either one-step ultrafiltration or ultracentrifugation. <i>Virus Research</i> , 2013, 175, 1-11.	2.2	25
111	Improving peptide relative quantification in MALDI-TOF MS for biomarker assessment. <i>Proteomics</i> , 2013, 13, 2967-2975.	2.2	21
112	Technical aspects and inter-laboratory variability in native peptide profiling: The CE-MS experience. <i>Clinical Biochemistry</i> , 2013, 46, 432-443.	1.9	181
113	Stem cells: Insights into the secretome. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2013, 1834, 2380-2384.	2.3	122
114	Proteasix: A tool for automated and large-scale prediction of proteases involved in naturally occurring peptide generation. <i>Proteomics</i> , 2013, 13, 1077-1082.	2.2	104
115	Redox proteomics: from residue modifications to putative biomarker identification by gel- and LC-MS-based approaches. <i>Expert Review of Proteomics</i> , 2013, 10, 537-549.	3.0	13
116	A combinatorial approach of Proteomics and Systems Biology in unravelling the mechanisms of acute kidney injury (AKI): involvement of NMDA receptor GRIN1 in murine AKI. <i>BMC Systems Biology</i> , 2013, 7, 110.	3.0	34
117	Drug Resistance in Natural Isolates of <i>Leishmania donovani</i> s.l. Promastigotes Is Dependent of Pgp170 Expression. <i>PLoS ONE</i> , 2013, 8, e65467.	2.5	18
118	Fetal Mesenchymal Stem Cells in Cancer Therapy. <i>Current Stem Cell Research and Therapy</i> , 2013, 8, 133-143.	1.3	8
119	Biomarkers for bladder cancer aggressiveness. <i>Current Opinion in Urology</i> , 2012, 22, 390-396.	1.8	32
120	Zinc β -2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer. <i>BJU International</i> , 2012, 110, E688-E693.	2.5	30
121	Evaluation of the Zucker Diabetic Fatty (ZDF) Rat as a Model for Human Disease Based on Urinary Peptidomic Profiles. <i>PLoS ONE</i> , 2012, 7, e51334.	2.5	59
122	Analysis of the urine proteome via a combination of multi-dimensional approaches. <i>Proteomics</i> , 2012, 12, 391-400.	2.2	30
123	Profilin 1 is a Potential Biomarker for Bladder Cancer Aggressiveness. <i>Molecular and Cellular Proteomics</i> , 2012, 11, M111.009449.	3.8	97
124	Human Amniotic Fluid-Derived Mesenchymal Stem Cells As Therapeutic Vehicles: A Novel Approach For the Treatment of Bladder Cancer. <i>Stem Cells and Development</i> , 2012, 21, 1097-1111.	2.1	52
125	Implementation of proteomic biomarkers: making it work. <i>European Journal of Clinical Investigation</i> , 2012, 42, 1027-1036.	3.4	151
126	Back to the future in bladder cancer research. <i>Expert Review of Proteomics</i> , 2011, 8, 295-297.	3.0	23

#	ARTICLE	IF	CITATIONS
127	TiO ₂ –ZrO ₂ affinity chromatography polymeric microchip for phosphopeptide enrichment and separation. <i>Lab on A Chip</i> , 2011, 11, 3113.	6.0	29
128	In vitro and in vivo properties of distinct populations of amniotic fluid mesenchymal progenitor cells. <i>Journal of Cellular and Molecular Medicine</i> , 2011, 15, 1896-1913.	3.6	79
129	Urine proteomics in kidney and urogenital diseases: Moving towards clinical applications. <i>Proteomics - Clinical Applications</i> , 2011, 5, 256-268.	1.6	20
130	Renal and Urinary Proteomics. <i>Proteomics - Clinical Applications</i> , 2011, 5, 211-213.	1.6	3
131	Subtle proteome differences identified between post-dormant vegetative and floral peach buds. <i>Journal of Proteomics</i> , 2011, 74, 607-619.	2.4	31
132	Systems biology to battle vascular disease. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1019-1022.	0.7	22
133	Analysis of Secreted Proteins for the Study of Bladder Cancer Cell Aggressiveness. <i>Journal of Proteome Research</i> , 2010, 9, 3243-3259.	3.7	44
134	Addressing the Challenge of Defining Valid Proteomic Biomarkers and Classifiers. <i>BMC Bioinformatics</i> , 2010, 11, 594.	2.6	108
135	Secretome proteomics for discovery of cancer biomarkers. <i>Journal of Proteomics</i> , 2010, 73, 2291-2305.	2.4	225
136	Comprehensive human urine standards for comparability and standardization in clinical proteome analysis. <i>Proteomics - Clinical Applications</i> , 2010, 4, 464-478.	1.6	139
137	Systems biology: opening new avenues in clinical research. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1015-1018.	0.7	36
138	Recommendations for Biomarker Identification and Qualification in Clinical Proteomics. <i>Science Translational Medicine</i> , 2010, 2, 46ps42.	12.4	273
139	A Tumor-Protective Role for Human Kallikrein-Related Peptidase 6 in Breast Cancer Mediated by Inhibition of Epithelial-to-Mesenchymal Transition. <i>Cancer Research</i> , 2009, 69, 3779-3787.	0.9	82
140	Application of Preparative Electrophoresis for Clinical Proteomics in Urine: Is it Feasible?. <i>Journal of Medical Biochemistry</i> , 2009, 28, 268-273.	1.7	2
141	Prediction of Muscle-invasive Bladder Cancer Using Urinary Proteomics. <i>Clinical Cancer Research</i> , 2009, 15, 4935-4943.	7.0	97
142	'Brukin2D': a 2D visualization and comparison tool for LC-MS data. <i>BMC Bioinformatics</i> , 2009, 10, S12.	2.6	2
143	Proteomic Feature Maps: A new visualization approach in proteomics analysis. <i>Journal of Biomedical Informatics</i> , 2009, 42, 644-653.	4.3	8
144	Chromosomal and proteome analysis of a new T24-based cell line model for aggressive bladder cancer. <i>Proteomics</i> , 2009, 9, 287-298.	2.2	26

#	ARTICLE	IF	CITATIONS
145	2nd Combined Working Group and Management Committee Meeting of Urine and Kidney Proteomics COST Action 29â€“30 March 2009, Nafplio, Greece. <i>Proteomics - Clinical Applications</i> , 2009, 3, 1017-1022.	1.6	9
146	Challenges of using mass spectrometry as a bladder cancer biomarker discovery platform. <i>World Journal of Urology</i> , 2008, 26, 67-74.	2.2	22
147	Establishment of a European Network for Urine and Kidney Proteomics. <i>Journal of Proteomics</i> , 2008, 71, 490-492.	2.4	35
148	Urine Sample Preparation and Protein Profiling by Two-Dimensional Electrophoresis and Matrix-Assisted Laser Desorption Ionization Time of Flight Mass Spectroscopy. <i>Methods in Molecular Biology</i> , 2008, 428, 141-157.	0.9	14
149	Search for Potential Markers for Prostate Cancer Diagnosis, Prognosis and Treatment in Clinical Tissue Specimens Using Amine-Specific Isobaric Tagging (iTRAQ) with Two-Dimensional Liquid Chromatography and Tandem Mass Spectrometry. <i>Journal of Proteome Research</i> , 2008, 7, 3146-3158.	3.7	92
150	Marked Defects in the Expression and Glycosylation of Î±2-HS Glycoprotein/Fetuin-A in Plasma from Neonates with Intrauterine Growth Restriction. <i>Molecular and Cellular Proteomics</i> , 2008, 7, 591-599.	3.8	43
151	Computational Methods and Algorithms for Mass-Spectrometry Based Differential Proteomics. <i>Current Proteomics</i> , 2007, 4, 223-234.	0.3	4
152	Molecular and Proteomic Characterization of Human Mesenchymal Stem Cells Derived from Amniotic Fluid: Comparison to Bone Marrow Mesenchymal Stem Cells. <i>Stem Cells and Development</i> , 2007, 16, 931-952.	2.1	268
153	Sample preparation and bioinformatics in MALDI profiling of urinary proteins. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 853, 20-30.	2.3	29
154	Overexpression of Î±-defensin is associated with bladder cancer invasiveness. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2006, 24, 97-108.	1.6	46
155	Characterization of the human urine proteome by preparative electrophoresis in combination with 2-DE. <i>Proteomics</i> , 2006, 6, 4346-4355.	2.2	62
156	Proteomic approaches in the search for disease biomarkers. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005, 814, 11-19.	2.3	71
157	Protein Profiling in Urine for the Diagnosis of Bladder Cancer. <i>Clinical Chemistry</i> , 2004, 50, 1438-1441.	3.2	46
158	Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. <i>Cancer</i> , 2004, 100, 1814-1822.	4.1	110
159	A Novel Approach Toward Development of a Rapid Blood Test for Breast Cancer. <i>Clinical Breast Cancer</i> , 2003, 4, 203-209.	2.4	128
160	Diagnosis of Ovarian Cancer Using Decision Tree Classification of Mass Spectral Data. <i>Journal of Biomedicine and Biotechnology</i> , 2003, 2003, 308-314.	3.0	134
161	A Novel Approach Toward Development of a Rapid Blood Test for Breast Cancer. <i>Clinical Breast Cancer</i> , 2003, 4, 203-209.	2.4	67
162	Application of a Novel Protein Chip Mass Spectrometry Technology for the Identification of Bladder Cancer-Associated Biomarkers. , 2003, 539, 47-60.		6

#	ARTICLE	IF	CITATIONS
163	Development of a Novel Proteomic Approach for the Detection of Transitional Cell Carcinoma of the Bladder in Urine. American Journal of Pathology, 2001, 158, 1491-1502.	3.8	408
164	Proteomic approaches to biomarker discovery in prostate and bladder cancers. Proteomics, 2001, 1, 1264-1270.	2.2	159
165	Proteomic approaches to biomarker discovery in prostate and bladder cancers. Proteomics, 2001, 1, 1264-1270.	2.2	2
166	Subcellular Trafficking of the Nuclear Receptor COUP-TF in the Early Embryonic Cell Cycle. Developmental Biology, 2000, 218, 284-298.	2.0	8
167	A Novel Sea Urchin Nuclear Receptor Encoded by Alternatively Spliced Maternal RNAs. Developmental Biology, 1996, 177, 371-382.	2.0	21
168	Very early and transient vegetal-plate expression of SpKrox1, a KrÄppel/Krox gene from Strongylocentrotus purpuratus. Mechanisms of Development, 1996, 60, 185-195.	1.7	41